Literature DB >> 26442590

Dopamine Transporter Activity Is Modulated by α-Synuclein.

Brittany Butler1, Kaustuv Saha1, Tanu Rana2, Jonas P Becker1, Danielle Sambo1, Paran Davari1, J Shawn Goodwin3, Habibeh Khoshbouei4.   

Abstract

The duration and strength of the dopaminergic signal are regulated by the dopamine transporter (DAT). Drug addiction and neurodegenerative and neuropsychiatric diseases have all been associated with altered DAT activity. The membrane localization and the activity of DAT are regulated by a number of intracellular proteins. α-Synuclein, a protein partner of DAT, is implicated in neurodegenerative disease and drug addiction. Little is known about the regulatory mechanisms of the interaction between DAT and α-synuclein, the cellular location of this interaction, and the functional consequences of this interaction on the basal, amphetamine-induced DAT-mediated dopamine efflux, and membrane microdomain distribution of the transporter. Here, we found that the majority of DAT·α-synuclein protein complexes are found at the plasma membrane of dopaminergic neurons or mammalian cells and that the amphetamine-mediated increase in DAT activity enhances the association of these proteins at the plasma membrane. Further examination of the interaction of DAT and α-synuclein revealed a transient interaction between these two proteins at the plasma membrane. Additionally, we found DAT-induced membrane depolarization enhances plasma membrane localization of α-synuclein, which in turn increases dopamine efflux and enhances DAT localization in cholesterol-rich membrane microdomains.
© 2015 by The American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Keywords:  addiction; amphetamine; dopamine; dopamine efflux; dopamine transporter; neurochemistry; synuclein

Mesh:

Substances:

Year:  2015        PMID: 26442590      PMCID: PMC4705954          DOI: 10.1074/jbc.M115.691592

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  67 in total

1.  Kinetic measurements give new insights into lipid membrane permeabilization by α-synuclein oligomers.

Authors:  Martin Stöckl; Mireille M A E Claessens; Vinod Subramaniam
Journal:  Mol Biosyst       Date:  2011-10-18

2.  Cationic modulation of human dopamine transporter: dopamine uptake and inhibition of uptake.

Authors:  N Chen; C G Trowbridge; J B Justice
Journal:  J Pharmacol Exp Ther       Date:  1999-09       Impact factor: 4.030

3.  An N-terminal threonine mutation produces an efflux-favorable, sodium-primed conformation of the human dopamine transporter.

Authors:  Rheaclare Fraser; Yongyue Chen; Bipasha Guptaroy; Kathryn D Luderman; Stephanie L Stokes; Asim Beg; Louis J DeFelice; Margaret E Gnegy
Journal:  Mol Pharmacol       Date:  2014-04-21       Impact factor: 4.436

4.  "Deconstruction" of the abused synthetic cathinone methylenedioxypyrovalerone (MDPV) and an examination of effects at the human dopamine transporter.

Authors:  Renata Kolanos; Ernesto Solis; Farhana Sakloth; Louis J De Felice; Richard A Glennon
Journal:  ACS Chem Neurosci       Date:  2013-10-31       Impact factor: 4.418

5.  Interaction of Na+, K+, and Cl- with the binding of amphetamine, octopamine, and tyramine to the human dopamine transporter.

Authors:  L B Li; M E Reith
Journal:  J Neurochem       Date:  2000-04       Impact factor: 5.372

6.  Immunocytochemical localization of the dopamine transporter in human brain.

Authors:  B J Ciliax; G W Drash; J K Staley; S Haber; C J Mobley; G W Miller; E J Mufson; D C Mash; A I Levey
Journal:  J Comp Neurol       Date:  1999-06-21       Impact factor: 3.215

7.  Flotillins regulate membrane mobility of the dopamine transporter but are not required for its protein kinase C dependent endocytosis.

Authors:  Tatiana Sorkina; John Caltagarone; Alexander Sorkin
Journal:  Traffic       Date:  2013-03-11       Impact factor: 6.215

8.  Membrane trafficking regulates the activity of the human dopamine transporter.

Authors:  H E Melikian; K M Buckley
Journal:  J Neurosci       Date:  1999-09-15       Impact factor: 6.167

9.  α-Synuclein stimulates a dopamine transporter-dependent chloride current and modulates the activity of the transporter.

Authors:  Jarod Swant; J Shawn Goodwin; Ashley North; Ahmad Abdul Ali; Joyonna Gamble-George; Sanika Chirwa; Habibeh Khoshbouei
Journal:  J Biol Chem       Date:  2011-10-11       Impact factor: 5.157

10.  Intracellular methamphetamine prevents the dopamine-induced enhancement of neuronal firing.

Authors:  Kaustuv Saha; Danielle Sambo; Ben D Richardson; Landon M Lin; Brittany Butler; Laura Villarroel; Habibeh Khoshbouei
Journal:  J Biol Chem       Date:  2014-06-24       Impact factor: 5.157

View more
  41 in total

Review 1.  α-Synuclein aggregation modulation: an emerging approach for the treatment of Parkinson's disease.

Authors:  Sushil K Singh; Aloke Dutta; Gyan Modi
Journal:  Future Med Chem       Date:  2017-06-20       Impact factor: 3.808

2.  Amphetamine Reverses Escalated Cocaine Intake via Restoration of Dopamine Transporter Conformation.

Authors:  Cody A Siciliano; Kaustuv Saha; Erin S Calipari; Steve C Fordahl; Rong Chen; Habibeh Khoshbouei; Sara R Jones
Journal:  J Neurosci       Date:  2017-11-24       Impact factor: 6.167

Review 3.  How can rAAV-α-synuclein and the fibril α-synuclein models advance our understanding of Parkinson's disease?

Authors:  Laura A Volpicelli-Daley; Deniz Kirik; Lindsay E Stoyka; David G Standaert; Ashley S Harms
Journal:  J Neurochem       Date:  2016-05-04       Impact factor: 5.372

4.  Dopamine transporter trafficking and Rit2 GTPase: Mechanism of action and in vivo impact.

Authors:  Rita R Fagan; Patrick J Kearney; Carolyn G Sweeney; Dino Luethi; Florianne E Schoot Uiterkamp; Klaus Schicker; Brian S Alejandro; Lauren C O'Connor; Harald H Sitte; Haley E Melikian
Journal:  J Biol Chem       Date:  2020-03-04       Impact factor: 5.157

Review 5.  Regulation of monoamine transporters and receptors by lipid microdomains: implications for depression.

Authors:  Joanne J Liu; Adrienne Hezghia; Saame Raza Shaikh; Joshua F Cenido; Ruth E Stark; J John Mann; M Elizabeth Sublette
Journal:  Neuropsychopharmacology       Date:  2018-06-28       Impact factor: 7.853

Review 6.  Conservative iron chelation for neurodegenerative diseases such as Parkinson's disease and amyotrophic lateral sclerosis.

Authors:  David Devos; Z Ioav Cabantchik; Caroline Moreau; Véronique Danel; Laura Mahoney-Sanchez; Hind Bouchaoui; Flore Gouel; Anne-Sophie Rolland; James A Duce; Jean-Christophe Devedjian
Journal:  J Neural Transm (Vienna)       Date:  2020-01-07       Impact factor: 3.575

7.  Clustered Kv2.1 decreases dopamine transporter activity and internalization.

Authors:  Joseph J Lebowitz; Jose A Pino; Phillip M Mackie; Min Lin; Cheyenne Hurst; Keeley Divita; Anthony T Collins; Dimitri N Koutzoumis; Gonzalo E Torres; Habibeh Khoshbouei
Journal:  J Biol Chem       Date:  2019-03-01       Impact factor: 5.157

Review 8.  The dopamine transporter: An unrecognized nexus for dysfunctional peripheral immunity and signaling in Parkinson's Disease.

Authors:  Phillip Mackie; Joe Lebowitz; Leila Saadatpour; Emily Nickoloff; Peter Gaskill; Habibeh Khoshbouei
Journal:  Brain Behav Immun       Date:  2018-03-15       Impact factor: 7.217

9.  Prolyl Oligopeptidase Regulates Dopamine Transporter Phosphorylation in the Nigrostriatal Pathway of Mouse.

Authors:  Ulrika H Julku; Anne E Panhelainen; Saija E Tiilikainen; Reinis Svarcbahs; Anne E Tammimäki; T Petteri Piepponen; Mari H Savolainen; Timo T Myöhänen
Journal:  Mol Neurobiol       Date:  2016-12-13       Impact factor: 5.590

Review 10.  Alpha-synuclein modulates dopamine neurotransmission.

Authors:  Brittany Butler; Danielle Sambo; Habibeh Khoshbouei
Journal:  J Chem Neuroanat       Date:  2016-06-19       Impact factor: 3.052

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.